Clinical characteristics of patients included in the 3 clinical series used to validate the TMTV/ECOG-PS model
| Characteristics . | PETAL (N = 510) . | GOYA (N = 1315) . | RW series (N = 349) . |
|---|---|---|---|
| Median age, y, n (range) | 62 (18-80) | 62 (18-86) | 66 (17-92) |
| Age ≥60 y, n (%) | 280 (54.9) | 758 (57.6) | 255 (73.1) |
| Sex | |||
| Male, n (%) | 279 (54.7) | 698 (53.1) | 169 (48.4) |
| Female, n (%) | 231 (45.3) | 617 (46.9) | 180 (51.6) |
| Histology | |||
| DLBCL not otherwise specified, n (%) | 479 (93.9) | 1186 (90.2) | 186 (92.1) |
| FL grade 3B, n (%) | 14 (2.7) | 0 (0) | 0 (0) |
| De novo transformed, n (%) | 17 (3.3) | 0 (0) | 10 (5.0) |
| Other, n (%) | 0 (0) | 129 (9.8) | 6 (3.0) |
| Missing, n | 0 | 0 | 147 |
| ECOG-PS | |||
| 0–1, n (%) | 451 (89.1) | 1152 (87.6) | 259 (74.2) |
| ≥2, n (%) | 55 (10.9) | 163 (12.4) | 90 (25.8) |
| Missing, n | 4 | 0 | 0 |
| Ann Arbor stage | |||
| I-II, n (%) | 214 (42.0) | 314 (23.9) | 93 (26.7) |
| III-IV, n (%) | 295 (58.0) | 1001 (76.1) | 256 (73.3) |
| Missing, n | 1 | 0 | 0 |
| Extranodal sites | |||
| <2, n (%) | 350 (68.8) | 854 (64.9) | 210 (62.3) |
| >2, n (%) | 159 (31.2) | 461 (35.1) | 127 (37.7) |
| Missing, n | 1 | 0 | 12 |
| Elevated LDH (>upper limit of normal) | |||
| No, n (%) | 222 (43.6) | 558 (42.6) | 130 (37.4) |
| Yes, n (%) | 287 (56.4) | 753 (57.4) | 218 (62.6) |
| Missing, n (%) | 1 | 4 | 1 |
| Age-adjusted IPI | |||
| 0-1, n (%) | 290 (57.1) | 686 (52.2) | 146 (41.8) |
| 2-3, n (%) | 218 (42.9) | 629 (47.8) | 203 (58.2) |
| Missing, n | 2 | 0 | 0 |
| IPI | |||
| 0-2, n (%) | 314 (61.7) | 736 (56.0) | 142 (40.7) |
| 3-5, n (%) | 195 (38.3) | 579 (44.0) | 207 (59.3) |
| Missing, n | 1 | 0 | 0 |
| Treatment | |||
| R-CHOP, n (%) | 486 (95.3) | 654 (49.7) | |
| G-CHOP, n (%) | — | 661 (50.3) | 349 (100) |
| Intensified CHOP/CHOP, n (%) | 24 (4.7) | — | — |
| TMTV (cm3) | |||
| Median, n (range) | 177 (1-8896) | 269 (2-8113) | 188 (0-3764) |
| TMTV >220 cm3, n (%) | 231 (45.3) | 725 (55.1) | 157 (45.0) |
| Combined TMTV and ECOG-PS risk factors∗ | |||
| 0 factor, n (%) | 270 (53.0) | 553 (42.1) | 164 (47.0) |
| 1 factor, n (%) | 192 (37.7) | 636 (48.4) | 123 (35.2) |
| 2 factors, n (%) | 47 (9.2) | 126 (9.6) | 62 (17.8) |
| Missing, n | 1 | ||
| Median follow-up, mo | 54.7 | 47.1 | 76.5 |
| Characteristics . | PETAL (N = 510) . | GOYA (N = 1315) . | RW series (N = 349) . |
|---|---|---|---|
| Median age, y, n (range) | 62 (18-80) | 62 (18-86) | 66 (17-92) |
| Age ≥60 y, n (%) | 280 (54.9) | 758 (57.6) | 255 (73.1) |
| Sex | |||
| Male, n (%) | 279 (54.7) | 698 (53.1) | 169 (48.4) |
| Female, n (%) | 231 (45.3) | 617 (46.9) | 180 (51.6) |
| Histology | |||
| DLBCL not otherwise specified, n (%) | 479 (93.9) | 1186 (90.2) | 186 (92.1) |
| FL grade 3B, n (%) | 14 (2.7) | 0 (0) | 0 (0) |
| De novo transformed, n (%) | 17 (3.3) | 0 (0) | 10 (5.0) |
| Other, n (%) | 0 (0) | 129 (9.8) | 6 (3.0) |
| Missing, n | 0 | 0 | 147 |
| ECOG-PS | |||
| 0–1, n (%) | 451 (89.1) | 1152 (87.6) | 259 (74.2) |
| ≥2, n (%) | 55 (10.9) | 163 (12.4) | 90 (25.8) |
| Missing, n | 4 | 0 | 0 |
| Ann Arbor stage | |||
| I-II, n (%) | 214 (42.0) | 314 (23.9) | 93 (26.7) |
| III-IV, n (%) | 295 (58.0) | 1001 (76.1) | 256 (73.3) |
| Missing, n | 1 | 0 | 0 |
| Extranodal sites | |||
| <2, n (%) | 350 (68.8) | 854 (64.9) | 210 (62.3) |
| >2, n (%) | 159 (31.2) | 461 (35.1) | 127 (37.7) |
| Missing, n | 1 | 0 | 12 |
| Elevated LDH (>upper limit of normal) | |||
| No, n (%) | 222 (43.6) | 558 (42.6) | 130 (37.4) |
| Yes, n (%) | 287 (56.4) | 753 (57.4) | 218 (62.6) |
| Missing, n (%) | 1 | 4 | 1 |
| Age-adjusted IPI | |||
| 0-1, n (%) | 290 (57.1) | 686 (52.2) | 146 (41.8) |
| 2-3, n (%) | 218 (42.9) | 629 (47.8) | 203 (58.2) |
| Missing, n | 2 | 0 | 0 |
| IPI | |||
| 0-2, n (%) | 314 (61.7) | 736 (56.0) | 142 (40.7) |
| 3-5, n (%) | 195 (38.3) | 579 (44.0) | 207 (59.3) |
| Missing, n | 1 | 0 | 0 |
| Treatment | |||
| R-CHOP, n (%) | 486 (95.3) | 654 (49.7) | |
| G-CHOP, n (%) | — | 661 (50.3) | 349 (100) |
| Intensified CHOP/CHOP, n (%) | 24 (4.7) | — | — |
| TMTV (cm3) | |||
| Median, n (range) | 177 (1-8896) | 269 (2-8113) | 188 (0-3764) |
| TMTV >220 cm3, n (%) | 231 (45.3) | 725 (55.1) | 157 (45.0) |
| Combined TMTV and ECOG-PS risk factors∗ | |||
| 0 factor, n (%) | 270 (53.0) | 553 (42.1) | 164 (47.0) |
| 1 factor, n (%) | 192 (37.7) | 636 (48.4) | 123 (35.2) |
| 2 factors, n (%) | 47 (9.2) | 126 (9.6) | 62 (17.8) |
| Missing, n | 1 | ||
| Median follow-up, mo | 54.7 | 47.1 | 76.5 |
Number of patients (%) presented unless otherwise specified.
G-CHOP, obinutuzumab CHOP.
Risk factors are TMTV >220 cm3 and ECOG-PS ≥2.